27-28 November 2013

Emmanuel PETIOT, CEO

Clean Green Event

DEINOVE

DEINOVE is a cleantech company that designs, develops and markets a new

generation of industrial processes based on ancestral bacteria with untapped

potential: the deinococci.

These new systems open the way for manufacturing of rare or technologically inaccessible

products:

• Second-generation biofuels (DEINOL)

• High added value biochemicals (DEINOCHEM)

• New antibiotics (DEINOBIOTICS SAS)

• Enzymes for the remediation of plastics (THANAPLAST™ lead by CARBIOS)

DEINOVE intends to provide new industrial technology standards that enable it to meet the great

world challenges: preparing for the post-oil era, switching to green chemistry, fighting against

antibiotic resistance and improving the life cycle of plastics.

THE DEINOCOCCUS WAY

2

DEINOVEKEY DATES

20092007 2008

Inception,

co-founders

Pr Miroslav RADMAN

Dr Philippe POULETTY

20132006 2010

DEINOL

EC1

2011 2012

OSEO funding

(€1.57 m)

Jacques BITON

CEO

IPO (€12 m)

Partnership with TEREOS

Partnership with VTT

OSEO funding (€1.4 m)

OSEO funding

(€6 m)

Deinobank (6 000 strains)

Initiation of DEINOL program

Deinobank (25 strains)

Proprietary technological platform

Initiation of DEINOBIOTICS program

Initiation of DEINOCHEM program

DEINOL EC2 (POC)THANAPLAST

™ program

1st data from the DEINOBIOTICS program

Changeover to 300L fermenters for DEINOL6M€ funding received for DEINOCHEM

from the French government

OSEO funding

(€1.15 m)

Market Cap: €53 m

Emmanuel PETIOT

CEO

3

2 5 31Team 40

STRATEGY, SKILLS & TECHNOLOGICAL KNOW-HOW

DEINOCHEM

DEINOVEEMPOWERING INNOVATION AND BIOTRANSFORMATION

DEINOL…and beyond

Second generation biofuels

Advanced

Biofuels

Ethanol

1.5G

Ethanol

2GIsoprenoids

Other

Molecules

Bio-

remediation

Chemicals, Specialty Chemicals, Natural molecules and

Bioremediation

• Fragrances• Flavours• Chemicals• Chemical

intermediates

• Chemicals• Chemical

intermediates• Sweeteners

• Animal Feed• Food• Cosmetics• Waste

remediation• Deinococcus

as a host strain

5

THE DEINOCOCCUS “MICRO-FACTORY”A SUM OF ECONOMIC AND ENVIRONMENTAL BENEFITS

HIGH GENOMIC STABILITY

Capacity to “capture” genetic

material from other organisms

in a highly stable manner

EXCEPTIONAL

ROBUSTNESS

Temperature, pH, desiccation

NON-PATHOGENIC

For human, animal

and environment

GREAT CAPACITY TO

DEGRADE BIOMASS

RARE OR TECHNOLOGICALLY

INACCESSIBLE PRODUCTS

STABLE AND

REPRODUCTIBLE

PRODUCTION SYSTEMS

GREAT TOLERANCE TO

PHYSICAL AND CHEMICAL

STRESS

BETTER RECOVERY

OF CO-PRODUCTS

REDUCED PRODUCTION

AND MAINTENANCE

COSTS

FERMENTATION CAPABILITY

FOR LONG CHAIN SUGARS

(C6, C5)THERMOPHILIC

Operating range

40°C to 50°C

6

THE PROPRIETARY TECHNOLOGICAL PLATFORMTHE BEST OF GENETIC ENGINEERING AND BACTERIOLOGY

ARCHIVING

Library of

cryopreserved

strains

PhysiologyHigh-throughput

growth assays

MetabolicFunctional tests

Gene expression

measurement

Microbiology

GenomicPCR

Sequencing

& Annotation

DEINOBANK

(6,000 clones)

Genetic & Metabolic

EngineeringGene insertion

Gene deletion

Sequence

optimization

LAB PILOT

INDUSTRIAL

PILOT

PRODUCTION

COLLECTION SELECTION OPTIMISATION SCALE UP

LEAD DEINOCOCCUS

CANDIDATE

S1 S2 S3 POC

Fermentation engineeringOptimization of

culture &

fermentation

processes

Industrial engineeringLab Assays

Test &

Integration

Samples

collection in

extreme

environment

7

A LARGE 6000 STRAINS DEINOBANK

Samples collection in various places and environments …

…original strains linked to a radiation selection

…new carbon sources

A large Deinobank (1800 strains) and lots of original strains (4200)

All the strains have been collected in conformity with international regulations (CBD)

Source of the new biocatalysts

INCLUDING NUMEROUS NEW BACTERIA

8

A TARGETED STRATEGY OF DEVELOPMENT ACCELERATE AND MAXIMISE THE CREATION OF VALUE

BIOFUELS

R&D Lab.Pilote

20202011 2012 2013 20142010 2015 2016 2017 2018 2019

Proof of concept

Industrial

piloteNon exclusive licences

GREEN CHEMICALS

Proof of concept

ANTIBIOTICS

R&DIndustrial

Dev.Non exclusive licences

R&DPreclinical

Dev.Exclusive licences

Proof of principle

9

THE WAY TO GREEN CHEMICALS

THE GREEN CHEMISTRY

Objective of the EU : 15% of renewable resources in chemistry in 2020*

• Today’s level : 8 - 10%

• Boosted by oil’s price increase

• Supported by public authorities

(REACH Directive, World pact on climate …)

A large number of players• Food industry, cosmetics, chemistry, oil

industry, biotechs, cleantechs, investment

funds, Coca Cola, Danone, Heinz…

A worldwide competition • Necessity to find reliable partners and

important financial resources

A FAST GROWING EMERGENT MARKET

The addressable markets for DEINOVE

*Green Univers, Panorama des Cleantech, January 2012Volume

Uni

t pric

e

CHEMICAL

INTERMEDIATES

Fuels

Chemistry

50M$

CAROTENIDS

Cosmetics

Agrochemicals

700m$

PROTEINS

Food

Biopharmaceuticals

100M$

HIGH ADDED

VALUE SUGARS

Food industry

1M$

ISOPRENOIDS

Fine chemicals

Fragrances

Biopharmaceutica

ls

70M$

ENZYMES

Chemistry

Biopharmaceutical

s

Hundreds of m$

N-BUTANOL

Solvents

Paints

Plastics

10M$

Plastics and polymers market (700 M$)

11

HO

O

OHHO

HO

HO

THE DEINOCOCCUS WAY GET THE BEST OUT OF BIOMASS

Conversion of

C5 & C6 sugars

HO

O

OHHO

HO

AcCoA

AcetoAcCoA

hydroxybutyrylCoA

crotonylCoA

butyrylCoA

MalonylCoA

H3C OH

Butanol

H3C CH

3

CH3

OH

H3C CH

3

HO

H3C

CH2

H2C CH

3

CH2

Geraniol Linalol Isoprene

H3C

OH

O

NH2

OH

O

O

H3C

OH

O

O

H3C CH

3

O

HO

O

CH2

H3C OH

H3C CH

3

OH

H3C

H3C

CH2

StyrEne

Isobutanol

Butanol

Isobutene

H2C

O

OH

Diaminobutane

Acrylate

NH2

H2N

SolventsPaints

Plastics

Cosmetics Fine chemistry

Animal feed

FERMENTATION

PATHWAY

AMINO ACIDS DERIVED

PATHWAY

ISOPRENOIDS PATHWAY

Bio-sourcedchemical products

112

DEINOCHEM

A smart strategy of diversification and exploitation of

DEINOL achievements:

• Strains of interest already identified

• A proprietary technological platform

• Reduced Time-to-market

A scale shift with the new Cap Sigma laboratories:

• Clean room for advanced robotics

• Automated strains’ design

• Parallel fermentors up to 20 L

6M€ FUNDING RECEIVED FROM FRENCH GOVERNMENT TO SUPPORT THIS STRATEGIC SECTOR

13

DEINOCHEM

Make DEINOVE’s platform profitable with high

added value developments:

• Specialty products / high price

• Target markets : Fine chemistry, flavours, cosmetics,

fragrances, animal feed

The Plus of DEINOVE technology:

• Constant productivity improvements

• Adaptability to industrial constraints: genetic plasticity,

solvents resistance, increased output, reduced production

costs

• Robustness and replicability of processes

AN ACTIVE PHASE OF VALUE CREATION

14

DEINOCHEM

The Plus of the Deinococci• Natural affinity for most of the targeted metabolic

pathways (ex: isoprenoids)

• Genetic plasticity (a key property to overcome

the complex steps)

• Resistance to solvents (growth under high

concentations)

• Adaptability to the substrate of the future:

lignocellulosic biomass

• Co-digest of C5 and C6 sugars (improvement of

the output)

• Thermophilic (improvement of the output and the

cost efficiency)

A NATURAL MARKET FOR DEINOVE The Plus of the DEINOL program

• Players common to biofuels and green

chemistry both known by DEINOVE

• A shared technological platform which

has proved its worth in a very

demanding field : 2G bioethanol

DEINOBANK

-

SELECTION

Physiology

Metabolomic

Microbiology

Genomic

OPTIMISATION

Genetic & Metabolic Engineering

Fermentation Engineering

SCALE UP

15

THE WAY TO 2G BIOFUELS

THE BIOFUELS MARKET +70% OF GROWTH ON THE 2006-2013 PERIOD

Bio

éthanol

BIOFUELS

Production & Consumption in EU

(million of liters)

15 000

2007 2008 2009 2010 2011 2012 2013

12 500

10 000

7 500

5 000

2 500

Bio

die

sel

9 000

8 000

7 000

6 000

5 000

4 000

3 000

2 000

1 000

0

10 000

Biodiesel consumption

Biodiesel production biodieselBiodiesel Importation biodieselBioethanol consumptionbioéthanolBioethanol production bioéthanolBioethanolproductionBioethanol importation bioéthanol

Bio

ethanol

Sources : EU FAS Posts

2006

17

THE BIOFUELS MARKETTHE INESCAPABLE EMERGENCE OF BIOMASS

1st

generation

biofuels

Cellulosic

bioethanol

Biodiesel from

biomass

Advanced

biofuels

0

5

10

15

20

25

30

35

40

Re

ne

wa

ble

F

ue

ls S

ta

nd

ard

(R

FS

2)

Billio

ns o

f G

allo

ns p

er Y

ea

r

20152010 2020

0

40

75

100

20

150

Bill

ion

liter

s / y

ear

(RFS

2)

Massachusetts Institute of Technology (MIT), September 2011

18

DEINOLFINDING THE STANDARD TO 2G BIOFUELS

PROJECT LEADER FINANCIAL SUPPORT

€ 8.9 million of grants and

repayable advances: the

largest funding for a biofuels

program in France

NO. 1 European manufacturer of bioethanol

Budget: € 21.4 million

ACADEMIC PARTNER ACADEMIC PARTNER

INDUSTRIAL PARTNER

SHAREHOLDER

Developing an integrated industrial process based on

Deinococcus to produce 2G bioethanol

19

Proof of

concept

THE DEINOL PROGRAMAN “ALL IN ONE” PROCESS WITH MULTIPLE BENEFITS

PROCESSES IN DEVELOPMENT

DEINOL

NON FOOD

BIOMASS

Distillation

2G bioethanol

Coproducts

Pretreatment

Enzymatic hydrolysis

70°C

Fermentation

37°C

NUTRITIONAL

QUALITY ++

LIGHT

YIELD ++

SINGLE STAGE AT 50°C

VERY ROBUST

NO ADDITIVE

20

DEINOLTHE POTENTIAL TECHNOLOGICAL STANDARD OF 2G BIOETHANOL

ENZYMES

+ YEAST

ENZYMES +

YEAST OR

OPTIMIZED

BACTERIA

DEINOL ADVANTAGES

Pretreatment Yes Yes Light Reduced costs

Conversion of complex sugars No Yes Improved Performance optimization

Fermentation of C5 and C6

sugars

No

C6 (yes)

C5 (no)

Yes Yield optimization

Assimilation of glycerol and

acetic acide

No No or ineffective Yes

Yield optimizationACOH toxicity reduced

Stability High Low Very high

ReproducibilityAvailability

Robustness Average Low Exceptional

ReproducibilityAvailabilityReduced maintenance

Temperature 35°C 35°C Up to 60°C

Reduced costs Energy efficiency +

NB : Due to its low levels of competitiveness (10€/l) and yield (± 1,5%), microalgae-based fuel is not shown in this table.

21

DEINOLAN ACCELERATED DEVELOPMENT

2011

PROCESS

PREVALIDATION

The optimized

strain degrade

more than 80% of

a wheat-based

biomass into

simple sugars

2012

PROOF OF

CONCEPT

Target:

process validation

in large fermenter

(300L) with SANOFI

and further

optimization

2013

PILOT LAB

Without additive,

the optimized

strain transforms

the same substrate

into bioethanol

with an alcohol

content of 3%

2014

INDUSTRIAL PILOT

2014-2015

PRODUCTION

Industrial validation

in operating plant

Market

production

Soft endosperm

Hard endosperm

Germ

Aleurone

Pericarp

Tip cap

1.5 & 2G BIOFUELS

22

CORPORATE AND FINANCIAL DATA

DEINOVEIN A NUTSHELL

• A unique position in the sector of plant chemistry: the Deinotechnologies

• Proprietary metabolic engineering tools to convert Deinococcus bacterial micro-factories into industrial

production systems

• A wide range of applications: all the bio sourced products that can be substituted for oil based products:

2G biofuels, chemistry intermediates, green chemistry, drugs…

• The proof of concept in 2G bioethanol with DEINOL, a1st

promising result in green chemistry, a market

worth more than 80M$

• The beginning of green chemistry exploration (hundreds of M$) with the 1st

step of DEINOCHEM, an

isoprenoid R&D dedicated program financed up to 6M€ by the Investissements d’Avenir sponsored by

the French Government

• A world-class scientific, engineers and managers team who delivers

• An academic network which gathers the world’s best specialists of synthetic biology and of the

Deinococcus

• A mid and long term ambition to live up the shareholders commitments thanks to the support of Truffle

Capital, and the French Government

24

DEINOVE

• 6m € funding received from French Government (Investissements d’Avenir) to

support the DEINOCHEM program (PR dated 13 11 13)

• Set up off standby Equity Facility PACEO® with Société Générale (within the

limit of 9% of the current share capital) in order to reinforce the flexibility and

the sources of financing (PR dated 31 10 13)

• On June 30th, 2013, sufficient cash covering company’s needs until Q3 2014

> Significant improvement compared to what was planned early 2013

> With equal resources and in spite of an intensification of research efforts

• Semester net loss decreased by 8%

> -1,3 m€ vs. -1,4 m€ for 2012

• The net financial position reaches +4,1 m€, VS +6,5 m€ at the end of 2012.

> It does not integrate the refund to CIR of 0,9 m€ received in July 2013 (PR dated July 15 2013)

KEY FINANCIAL FIGURES

25

MANAGEMENT

Emmanuel PETIOT

CEO

Former Sales Director at

NOVOZYMES North

America Inc.

EDHEC, École CentraleParis

Jean Paul LEONETTI,

PhD

VP of R&D

Former team leader at

CBPS (CNRS).

PhD in Microbiology, University of Montpellier

Julien COSTE

CFO

Former CFO at Neuro3D and

at the French branch of

Publicis Healthcare

Communication Group

(PHCG).

ESC Grenoble, Paris Dauphine

Elisabetta CASTELLI,

PhD

Director of

Communications & IR

Former CEO of the Equity

branch of Deutsch Bank

(BT Alex Brown).

London School of Economics

Nagib WARD

VP, Business

Development

Former Marketing and BD

Manager at Novozymes

North America Inc.

Degree in Chemistry and Biochemistry, NorthernMichigan University MBA, Marquette University

A TEAM OF EXPERTS WITH INTERNATIONAL BACKGROUND

26

BOARD OF DIRECTORSWOLRD-CLASS PERSONALITIES

Dr Philippe POULETTY

Non-executive Chairman

Co-founder

Co-Fonder & General Partner

of TRUFFLE CAPITAL

Pr Frédéric DARDEL

Co-founder

Chairman of the PARIS

DESCARTES UNIVERSITY

Christian PIERRET

Former French Minister

of Industry

Paul-Joël DERIAN

Head of Group R&D SUEZ

ENVIRONNEMENT

Pr Rodney J. ROTHSTEIN

Professor of Genetics,

COLUMBIA UNIVERSITY,

New York USA

Nabil SAKKAB

Former Head of Group R&D

PROCTER & GAMBLE

Bruno WEYMULLER

Former Head of Group

Strategy TOTAL

27

EQUITY STORYSHARE CAPITAL & STOCK EVOLUTION IN 2013

Capital (30.06.13)

(totaly dilluted)

Share Price Evolution in 2013

52..43%

5.96%2,05%

6,18%

33.38%

AUM of TruffleCapitalScientificfounders*Tereos EU

Management &Board membersFree float

* M. Radman, Paris Descartes University

Number of shares: 5.002 million

(5.869 million totaly dilluted)

28

CONTACTS

Emmanuel PETIOT

CEO

Phone : + 33 6 13 80 25 30

emmanuel.petiot@deinove.com

Elisabetta CASTELLI

VP, IR and Communication

Phone + 33 6 13 66 39 39

elisabetta.castelli@deinove.com

29